- RFP #2025-053: Anti-Pertussis Toxin IgG Correlate of Protection for Maternal Vaccination Study
-
Despite high rates of vaccination with acellular pertussis (aP) vaccines, the incidence of Bordetella pertussis infections is on the rise in the United States and other high-income countries.
Because the first routine pertussis vaccination occurs at 6–8 weeks of age, infants less than 2 months of age have the highest rate of serious clinical complications requiring hospitalization and the highest mortality rate following pertussis exposure.
PATH is seeking a qualified testing facility to determine the required dose of anti-pertussis toxoid serum generated in adult baboons to achieve a titer of 5 international units (IU) when administered to eight-week-old baboons.
Find detailed scope of work and requirements here.
Our principles
PATH subscribes to principles of simplicity and economy in procurement operations. We comply with US government procurement integrity regulations, anti-terrorism regulations, and Equal Employment Opportunity legislation.